NervGen Pharma Corp. (NGEN)

NervGen Pharma Corp. is a clinical-stage biotechnology company headquartered in Vancouver, British Columbia, whose common stock trades on the Nasdaq under the ticker NGEN. The company develops treatments intended to promote repair of the nervous system after injury or disease.

NervGen's lead candidate, NVG-291, is a peptide therapy designed to block protein tyrosine phosphatase sigma, a receptor that interacts with molecules in scar tissue and inhibits nerve regeneration. By interfering with this signal, the drug aims to enable nerve fibers to regrow and form new connections. The company is studying NVG-291 in people with chronic and subacute spinal cord injury.

Beyond spinal cord injury, NervGen is exploring the potential of its approach in other conditions where nerve damage plays a role, such as stroke and multiple sclerosis.